Cholesterol goal attainment in patients with coronary heart disease and elevated coronary risk: Results of the Hong Kong Hospital Audit Study

Value in Health

Volumn 11, Issue SUPPL. 1, 2008, Pages

  Lee, Kenneth K C ^a   Lee, Vivian W Y ^a   Chan, Wai Kwong ^b   Lee, Benjamin S C ^a   Chong, Agnes C Y ^a   Wong, Jasper C L ^a   Yin, Don ^d   Alemao, Evo ^d   Tomlinson, Brian ^c  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b UNITED CHRISTIAN HOSPITAL   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Coronary disease; Hydroxymethylglutaryl CoA reductase inhibitors; Hypercholesterolemia; Prevention and control

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; EZETIMIBE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; STATINE DERIVATIVE;

ADULT; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY RISK; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HONG KONG; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 41749084427     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00372.x     Document Type: Conference Paper

References (46)

1. World Health Organization. Atlas of heart disease and stroke: types of cardiovascular disease 2005. Available from: http://www.who.int/ cardiovascular_diseases/resources/atlas/en/ [Accessed April 10, 2006].
2. Fu FH. The prevalence of cardiovascular disease risk factors of Hong Kong Chinese. J Sports Med Phys Fitness 2001 41 : 491 9.
3. Ko PTH. Sudden cardiac death: the war is far from over. Hong Kong Med J 2003 9 : 317 8.
4. Hong Kong Department of Health. Annual Report 2003/2004: publications and records. Available from: http://www.esdlife.com [Accessed May 23, 2006].
5. Lee VWY, Chan WK, Lam NLC, et al. Cost of acute myocardial infarction in Hong Kong. Dis Manage Health Outcomes 2005 13 : 281 5.
6. Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991 303 : 276 82.
7. Tao SC, Huang ZD, Wu XG, et al. CHD and its risk factors in the People's Republic of China. Int J Epidemiol 1989 18 (Suppl. S159 63.
8. Schwartzkopff W, Schleicher J, Pottins I, et al. Lipids, lipoproteins, apolipoproteins, and other risk factors in Chinese men and women with and without myocardial infarction. Atherosclerosis 1990 82 : 253 9.
9. Chan WK, Chiu A, Ko GT, et al. Ten-year cardiovascular risk in a Hong Kong population. J Cardiovasc Risk 1999 6 : 163 9.
10. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004 350 : 1495 504.
11. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005 352 : 1425 35.
12. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004 291 : 1071 80.
13. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 110 : 227 39.
14. Van Ganse E, Laforest L, Alemao E, et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005 21 : 1389 99.
15. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000 160 : 459 67.
16. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999 83 : 1303 7.
17. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med 1996 100 : 605 10.
18. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996 100 : 197 204.
19. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000 101 : 207 13.
20. Adult Treatment Panel III. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 2001 285 : 2486 97.
21. Van Ganse E, Souchet T, Laforest L, et al. Ineffectiveness of lipid-lowering therapy in primary care. Br J Clin Pharmacol 2005 59 : 456 63.
22. Goettsch WG, Yin DD, Alemao E, et al. Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. Curr Med Res Opin 2004 20 : 1025 33.
23. Ose L, Skjeldestad FE, Bakken IJ, et al. Lipid management and cholesterol goal attainment in Norway. Am J Cardiovasc Drugs 2006 6 : 121 8.
24. Garcia Ruiz FJ, Marin IA, Perez-Jimenez F, et al. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study. Pharmacoeconomics 2004 22 (Suppl. 3 S1 12.
25. Primatesta P, Poulter NR. Lipid levels and the use of lipid-lowering agents in England and Scotland. Eur J Cardiovasc Prev Rehabil 2004 11 : 484 8.
26. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 2000 321 : 1322 5.
27. Van Ganse E, Souchet T, Laforest L, et al. Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study. Atherosclerosis 2006 185 : 58 64.
28. Ito MK, Delucca GM, Aldridge MA. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease-related events. J Cardiovasc Pharmacol Ther 2001 6 : 129 35.
29. Lindgren P, Borgstrom F, Stalhammar J, et al. Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice. Eur J Cardiovasc Prev Rehabil 2005 12 : 530 4.
30. Foley KA, Simpson RJ Jr, Crouse JR III, et al. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003 92 : 79 81.
31. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997 80 : 106 7.
32. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003 10 (Suppl. S1 10.
33. Gagné C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002 90 : 1084 91.
34. Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004 148 : 447 55.
35. Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005 80 : 587 95.
36. Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005 149 : 464 73.
37. Ballantyne CM, Lipka LJ, Sager PT, et al. Long-term safety and tolerability profile of ezetimibe and atorv astatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract 2004 58 : 653 8.
38. Mok HY, von Bergmann K, Grundy SM. Effects of continuous and intermittent feeding on biliary lipid outputs in man: application for measurements of intestinal absorption of cholesterol and bile acids. J Lipid Res 1979 20 : 389 98.
39. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005 102 : 8132 7.
40. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002 40 : 2125 34.
41. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003 107 : 2409 15.
42. Armstrong EP, Zachry WM III, Malone DC. Cost-effectiveness analysis of simvastatin and lovastatin/extended-release niacin to achieve LDL and HDL goal using NHANES data. J Manag Care Pharm 2004 10 : 251 8.
43. Xydakis AM, Guyton JR, Chiou P, et al. Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol 2004 94 : 795 7.
44. Lee SS, Cheung PY, Chow MS. Benefits of individualized counseling by the pharmacist on the treatment outcomes of hyperlipidemia in Hong Kong. J Clin Pharmacol 2004 44 : 632 9.
45. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs - do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995 332 : 1125 31.
46. Simons LA, Simons J, McManus P, et al. Discontinuation rates for use of statins are high [letter]. BMJ 2000 321 : 1084.